Second Primary Cancers and Surveillance

NCI lists second primary cancers among the late effects of treatment. These are new cancers that can develop years after the first one.

A recurrence is different. That is the original cancer coming back. The two are handled differently, so the difference is not a wording detail. If a new finding turns up, ask your team directly which of the two they think it is, and what testing settles the question.

NCI's Division of Cancer Epidemiology and Genetics puts it this way. "Nearly one in five cancers diagnosed today occurs in an individual with a previous diagnosis of cancer."

Part of that is success. The survivor population in the United States grew from about 3.5 million in the 1970s to more than 17 million.

That figure describes the whole country, not you. Your own risk depends on what you were treated with, how old you were, whether you carry an inherited gene change, and what you do now.

Second cancers do not all arrive at the same time. NCI's childhood late-effects summary describes two separate patterns.

Blood cancers come first. Myelodysplastic syndrome and acute myeloid leukemia can appear within 10 years of treatment. The risk follows two drug groups.

• Alkylating agents: cyclophosphamide, ifosfamide, mechlorethamine, melphalan, and busulfan.
• Topoisomerase II inhibitors, such as etoposide.

Solid tumors come later. These typically appear 10 or more years after treatment. That is long after most people have stopped thinking about their cancer history.

NCI links specific second cancers to specific exposures.

• Breast cancer. Risk rises after high-dose radiation therapy to the chest. Alkylating agents and anthracyclines also raise it.
• Thyroid cancer. Follows radiation therapy to the neck given for Hodgkin lymphoma, acute lymphoblastic leukemia, or brain tumors.
• Lung cancer. Follows radiation to the chest for Hodgkin lymphoma or bone cancer. The risk is higher in people who smoke.
• Stomach, liver or colorectal cancer. Follows radiation therapy to the abdomen or pelvis, chemotherapy, or both.
• Nonmelanoma skin cancer. Follows radiation treatment. It also follows the vinca alkaloid drugs, meaning vincristine and vinblastine.

Read that list against your own records, not against your diagnosis name. Two people with the same cancer can have completely different second-cancer risks, because one had radiation and one did not.

MedlinePlus is direct about this. "Tamoxifen may cause cancer of the uterus (womb), strokes, and blood clots in the lungs."

If you take tamoxifen, tell your doctor right away about any of these:

• Abnormal vaginal bleeding.
• Irregular menstrual periods.
• Changes in vaginal discharge, especially if it turns bloody, brown, or rusty.
• Pelvic pain or pressure.

MedlinePlus also gives a standing instruction. "Keep all appointments with your doctor. You will need to have gynecological examinations (examinations of the female organs) regularly to find early signs of cancer of the uterus."

This is not a reason to stop the drug. It is a reason to keep the appointments.

NCI says a treatment summary should include:

• The date you were diagnosed.
• The type of cancer you had.
• All surgeries, radiation therapy sites and amounts, and chemotherapy drugs and doses.
• Key lab reports, x-ray reports, CT scans, and MRI reports.
• A list of signs and symptoms to watch for, and possible long-term effects.
• Contact information for all health professionals involved in your treatment.

Two items on that list are the ones that go missing: radiation sites and amounts, and chemotherapy drugs and doses. Without those, nobody can tell you which second cancers apply to you. A primary care doctor cannot guess your radiation field from a discharge letter.

Request them from the treating center now, while the records are still easy to pull. Centers close. Systems get replaced. Records get archived.

NCI states that all cancer survivors should have follow-up care, and that check-ups may include bloodwork, tests and procedures.

Surveillance is not a full-body scan every year. It is a short list of specific tests aimed at the risks your own treatment created. Alongside that sits the ordinary screening everyone your age gets.

Both halves matter, and the second half is the one that slips. Mammograms, colonoscopy and cervical screening still apply to you. It is easy to assume oncology has all of it covered when nobody has actually said so.

Ask for your list of signs and symptoms to watch for. NCI says that list belongs in the treatment summary. Yours should be personal to your treatment, not a general leaflet.

NCI puts it simply. Its late-effects summary says smoking, heavy drinking, illegal drug use, poor sun protection and inactivity may worsen treatment-related organ damage and may raise the risk of second cancers.

Most second-cancer risk is already set by treatment you have finished. Smoking is not. And if you had radiation to the chest, this one matters more for you than for the general population, because lung cancer risk after chest radiation runs higher in people who smoke.

Take these to the next follow-up visit.

• Which second cancers are linked to the exact treatment I had?
• Which extra tests do I need because of that, and starting at what age?
• Which routine screenings should I still get on the normal schedule?
• Who orders and tracks these tests, oncology or primary care?
• Is genetic testing worth doing in my case?
• Can I have my radiation fields and doses, and my chemotherapy drugs and doses, in writing?

This page describes patterns that apply across large groups. It cannot set your personal screening schedule or tell you whether a symptom is a new cancer. That depends on your records, your age, your family history, and a clinician who has read them.

• Second Primary Cancers Among Cancer Survivors — NCI Division of Cancer Epidemiology and Genetics
• Late Effects of Treatment for Childhood Cancer (PDQ), Patient Version — National Cancer Institute
• Late Effects of Cancer Treatment — National Cancer Institute
• Follow-Up Medical Care for Cancer Survivors — National Cancer Institute
• Tamoxifen — MedlinePlus Drug Information